Publicaciones en colaboración con investigadores/as de Harvard Medical School (65)

2024

  1. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

    Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

  2. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2023

  1. Analysis of the Updated ACC/AHA Coronary Revascularization Guidelines With Implications for Cardiovascular Anesthesiologists and Intensivists

    Journal of Cardiothoracic and Vascular Anesthesia, Vol. 37, Núm. 1, pp. 135-148

  2. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  3. Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

    Frontiers in Immunology, Vol. 14

  4. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  5. Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile

    Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674

  6. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

    European Journal of Cancer, Vol. 178, pp. 23-33

  7. Impact of Long-Term Evoked Compound Action Potential Controlled Closed-Loop Spinal Cord Stimulation on Sleep Quality in Patients With Chronic Pain: An EVOKE Randomized Controlled Trial Study Subanalysis

    Neuromodulation, Vol. 26, Núm. 5, pp. 1030-1038

  8. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  9. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2998-3008

  10. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review

    JACC: CardioOncology, Vol. 5, Núm. 6, pp. 715-731

  11. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997

  12. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease

    Nature Cardiovascular Research, Vol. 2, Núm. 2, pp. 144-158

  13. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

2022

  1. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 14

  2. ANTES Program: One Year on

    Archivos de Bronconeumologia

  3. An HNRNPK-specific DNA methylation signature makes sense of missense variants and expands the phenotypic spectrum of Au-Kline syndrome

    American Journal of Human Genetics, Vol. 109, Núm. 10, pp. 1867-1884

  4. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  5. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182